We are a contract research organization (CRO) that increase the speed for your pre-clinical drug development
BioReperia has developed a unique zebrafish tumor xenograft (ZTX™) technology platform that provides functional in-vivo data to evaluate treatment efficacy for tumor regression and metastasis inhibition in only 5 days.
Our goal is to increase the speed and accuracy of preclinical drug development for cancer treatment, enabling you to select the lead candidates with the highest potential to succeed in less time.
We provide a humanized, in-vivo oncology drug discovery platform, ZTX™ ONCOLEADS, that mimics the complex tumor environment, allowing you to select the best lead candidates for further pharmaceutical development within 5 days.
Our ZTX™ PREDICT platform identifies the most efficient anti-cancer drug for individual patients within 5 days, providing clinical decision support for pharmaceutical or surgical treatment.
BioReperia supplied us with zebrafish larvae and they performed toxicology tests of our compounds prior to our electrophysiological recordings. The collaboration with BioReperia has worked very well, they are responsive to our needs and are willing to share their knowledge. Without their flexibility and knowledge, our recordings would have been very difficult to perform.
Bioreperia's innovative approach based on ZTX™ ONCOLEADS has been very useful for screening and accelerating our discovery program toward mammalian testing. From support of study design to full interpretation of results, our experience has been rewarding. Finally, the Swedish management style was quite agreeable on a more personal level.
BioReperia is a contract research laboratory (CRO) that is dedicated to providing a unique service to accelerate anti-cancer drug discovery. Our goal is to assist each customer to efficiently select the best new drug candidates and move them rapidly from preclinical to early stage clinical development. We can make something great together!
Ask your questions or request an introductory call.